Redefining Skin Biopsy
An innovative elliptical punch biopsy device that delivers superior cosmetic outcomes without compromising clinical efficiency
The Problem
Suboptimal Cosmesis
Conventional circular punch biopsies often leave puckered, widened, and cosmetically unfavorable scars
Time Constraints
Traditional fusiform excisions yield better scars but are too time-consuming for high-volume clinical settings
Limited Options
Clinicians must choose between speed and cosmetic outcome, with no optimal middle ground
Our Solution
Fig. 1B — Assembled device (US Patent No. 11,805,997 B2)
Elliptical Punch Biopsy Device
The Revedeon elliptical punch biopsy device bridges the gap between speed and cosmetic outcome. Our patented technology produces an elliptical, fusiform-like defect without the extra time and complexity of traditional elliptical excisions.
Superior Cosmesis
Creates linear wounds that align with relaxed skin tension lines
Maintained Efficiency
Fast procedure time comparable to circular punches
Adjustable Depth
Simple depth control without complex mechanisms
Easy Adoption
Intuitive design fits seamlessly into existing workflows
Multiple Sizes
Designed to accommodate a range of skin lesion sizes (4–12 mm)
Device in Action
Watch the elliptical punch biopsy device compared to traditional circular punches
Technology & Innovation
Patented Design
The device incorporates a fusiform blade that creates an elliptical wound while maintaining the simplicity and speed of a traditional punch biopsy. The approach effectively converts a punch biopsy into a miniature elliptical excision — a punch excision — without the added time. This patented design addresses a fundamental limitation in current dermatologic practice.
Clinical Advantages
By producing wounds that better align with relaxed skin tension lines, the device reduces puckering and may improve healing outcomes. The result is a more cosmetically favorable linear scar that may benefit both patients and practitioners.
Workflow Integration
Designed for seamless integration into high-volume clinical settings, the device maintains procedural efficiency while delivering superior cosmetic results. The adjustable depth control adds precision without adding complexity.
Comparative Advantages
vs. Circular Punches
- Better cosmetic outcomes
- Reduced scarring and puckering
- Similar procedural speed
- Comparable cost profile
vs. Fusiform Excisions
- Significantly faster procedure
- Simpler technique
- Similar cosmetic results
- Better workflow efficiency
vs. Complex Systems
- Lower manufacturing cost
- Easier adoption curve
- No complex mechanisms
- Proven design principles
Market Opportunity
Addressing a Clear Clinical Need
The elliptical skin biopsy device was developed through firsthand clinical insights in fellowship-trained Mohs micrographic surgery, translating a persistent procedural challenge into an innovative solution.
Target Markets
Dermatology Practices
High-volume dermatologists performing routine diagnostic biopsies and skin cancer evaluations
Plastic Surgery
Cosmetic and reconstructive surgeons prioritizing aesthetic outcomes in facial and visible areas
Primary Care
Family physicians and internal medicine practitioners performing outpatient skin procedures
Advanced Practice
Physician assistants and nurse practitioners conducting skin biopsies in clinic settings
Market Drivers
Growing Skin Cancer Incidence
Rising global rates of skin cancer drive increased diagnostic biopsy volumes across all practice settings
Cosmetic Expectations
Patient demand for optimal cosmetic outcomes continues to grow, particularly in aesthetic-conscious markets
Reimbursement Alignment
Compatible with existing reimbursement frameworks for small excisions, facilitating adoption
Practice Differentiation
Enables clinicians to differentiate their practice through improved patient outcomes and satisfaction
Development Roadmap
Revedeon seeks a manufacturing partner to advance this technology through commercialization, handling prototype development, 510(k) clearance, manufacturing, and distribution under a royalty-based arrangement.
Design for Manufacturing
Refine design specifications and optimize for large-scale production
Preclinical Testing
Complete usability and user-experience evaluations with target clinicians
510(k) Clearance
Navigate FDA premarket notification and prepare regulatory submissions
Clinical Adoption
Establish early clinical use and collect post-market data on outcomes and satisfaction
About the Founder
Alexander Reid, MD
Fellowship-Trained Mohs Micrographic Surgeon
Dr. Reid brings extensive clinical experience in cutaneous oncology and procedural dermatology to the development of innovative surgical tools designed to improve patient outcomes.
Education & Training
- Medical School: University of Michigan Medical School
- Dermatology Residency: University of Iowa
- Mohs Fellowship: Geisinger Medical Center
Vision
Through years of high-volume clinical practice performing skin cancer surgeries and diagnostic biopsies, Dr. Reid identified a persistent gap in available tools: conventional circular punch biopsies routinely produce suboptimal cosmetic outcomes, yet time constraints make traditional fusiform excisions impractical for most settings.
This device represents a direct translation of clinical insight into a practical solution — delivering improved cosmetic outcomes without compromising the efficiency that busy practices require.
Patent Information
US Patent No. 11,805,997 B2
Title: Skin Biopsy Device
Assignee: Revedeon, LLC
Inventor: Alexander Reid, MD
Date of Patent: November 7, 2023
The patent covers devices and methods for performing skin biopsies with consistent depth and shape. The device provides for reducing or eliminating operator error and inter-operator variability by generating the same forces across multiple uses, while also incorporating a fusiform blade to eliminate puckering of wound closures.
Frequently Asked Questions
What is the Revedeon elliptical punch biopsy device?
A patented surgical instrument (US Patent No. 11,805,997 B2) that produces fusiform-like wound geometry at the speed of a conventional circular punch biopsy — eliminating dog-ear formation and improving cosmetic outcomes without additional procedural time.
Is it FDA cleared or commercially available?
No. The device is a patented concept and is not yet FDA cleared or commercially available. Revedeon is seeking a manufacturing partner to advance the device through 510(k) premarket clearance and commercialization.
How does it differ from a standard circular punch biopsy?
Conventional circular punches create round wounds that misalign with relaxed skin tension lines, producing puckered, cosmetically unfavorable scars (standing cones). The Revedeon device uses a fusiform blade to create an elliptical wound aligned with skin tension lines — yielding results comparable to a fusiform excision at circular-punch speed.
What sizes will be available?
The device is designed in a range of sizes from 4 to 12 mm, accommodating the variety of lesion sizes encountered in routine dermatologic and procedural practice.
Who invented the device?
The device was invented by Dr. Alexander Reid, MD, a fellowship-trained Mohs micrographic surgeon based in Waterloo, Iowa. He completed medical school at the University of Michigan, dermatology residency at the University of Iowa, and his Mohs surgery fellowship at Geisinger Medical Center.
What type of manufacturing partner is Revedeon seeking?
Revedeon is seeking an established medical device manufacturer to take on prototype development, 510(k) FDA clearance, manufacturing, and distribution under a royalty-based arrangement. Dr. Reid provides clinical expertise and technical collaboration throughout the process.
Partner With Revedeon
The device is patented and ready for the right industry partner to advance the elliptical punch biopsy through commercialization. We welcome inquiries from manufacturers, distributors, and strategic collaborators.
Clinical Feedback
Practicing dermatologists, Mohs surgeons, and proceduralists — share your experience with current circular punch limitations and help inform the device design.
Share FeedbackPartnership Inquiry
Medical device manufacturers and industry partners interested in advancing the elliptical punch biopsy from patented concept to commercial product.
Submit Inquiry